Opportunity Identification – Leading Specialty Biopharma

The client sought support in R&D asset screening and prioritization to guide strategic in-licensing initiatives in the oncology space within 8 indications, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and triple-negative breast cancer (TNBC).

Our Solution

GlobalData assisted the client to design screening and prioritization criteria for target pipeline products, and then leveraged our proprietary Pharma Intelligence Center databases to identify potential pipeline products, filtering them according to pre- specified screening criteria. Using our proprietary prioritization tool, GlobalData identified oncology assets that are most likely fit to our client’s interest.

Outcome

GlobalData compiled a database of 357 pipeline assets within the 8 indications of interest and meeting specific inclusion criteria. A prioritization exercise was performed to determine the potentially most attractive assets, and GlobalData Consulting provided top- line assessment for the top 20 assets.